All manuscripts
Publications VST Cells

Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy

Published Journal Frontiers in Immunology

Share
11 pages Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy — Frontiers in Immunology, 2020

Overview

This study characterizes CMV-specific T lymphocytes (VSTs) expanded rapidly for adoptive immunotherapy. Using G-Rex® technology with IL-2, IL-7, and IL-15, researchers achieved a scalable process yielding functional, cytotoxic T cells. The method ensures high specificity and safety for treating viral infections.

What this paper found

A 14-day expansion process using pp65 peptide-pulsed autologous monocyte-derived dendritic cells generated a cytomegalovirus-specific T cell product from healthy seropositive donors that is amenable to cGMP transfer. Thawed PBMC were seeded with the dendritic cells at a 1:10 ratio in G-Rex® devices and cultured with IL-2, IL-7, IL-15 and anti-CD3/anti-CD28 antibodies. Nine batches gave a median of 43.3E+06 cells (range 4.5E+06 to 100.1E+06) from 1E+06 PBMC seeded. The product contained both CD4+ and CD8+ T cells, and IFN-γ+ CD3+ cells expanded at least 98.89-fold. Cells lysed pp65-pulsed autologous blasts, and alloreactive lysis of non-pulsed allogeneic blasts stayed below 5%.

Note: In vitro characterization using cells from healthy donors; the authors note that translation of production and validation to cGMP standards is a future step.

In conclusion, we have shown a feasible and scalable process that can be easily transferred to cGMP standards and that generates a safe and functional product. — Marta Grau-Vorster, María López-Montañés, Ester Cantó, Joaquim Vives, Irene Oliver-Vila, Pere Barba, Sergi Querol, Francesc Rudilla, Frontiers in Immunology

Study details

Authors
Marta Grau-Vorster, María López-Montañés, Ester Cantó, Joaquim Vives, Irene Oliver-Vila, Pere Barba, Sergi Querol, Francesc Rudilla
Institution
Cell Therapy Service, Banc de Sang i Teixits, Barcelona, Spain · Transfusion Medicine Group, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain · Musculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain · Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain · Hematology Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
Journal
Frontiers in Immunology
Year
2020
PMID / PMC
PMID: 32161589 · PMC
Cell type(s)
VST Cells
Application area
Infectious disease
Study phase
Preclinical

How G-Rex® was used

Thawed PBMC from CMV-seropositive healthy donors were seeded at 0.25-1.0E+06 cells/cm² with pp65-pulsed autologous dendritic cells at a 1:10 DC:PBMC ratio in a G-Rex® culture system. Cells were expanded for 14 days in RPMI with 10% human AB serum, with IL-2, IL-7, IL-15 and anti-CD3/anti-CD28 added at day 5 and cytokines renewed on days 7, 9 and 12. Nine batches were produced, averaging 42.2-fold expansion.

Explore related

Full citation

Grau-Vorster M, López-Montañés M, Cantó E, et al. Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy. Front Immunol. 2020;11:271.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →